Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals (myBIOM)

3. November 2026 aktualisiert von: Chr Hansen - part of Novonesis

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study

The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.

The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

90

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Blackpool
      • Cork, Blackpool, Irland, T23 R50R

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

45 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Be able to give informed consent.
  2. Be between 45 to 70 years of age (inclusive).
  3. BMI <40.0 kg/m²
  4. Willing to maintain current level of physical activity and diet during the participation in the study.
  5. Experience ≤4 bowel movements per week within the month prior to screening
  6. Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening.
  7. Willing to consume the study product daily for the duration of the study.
  8. Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).

Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period

Exclusion Criteria:

  1. Has a history of drug and/or alcohol abuse.

  2. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  3. Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.

  4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:

    1. diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)
    2. GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.
    3. history of CVD
    4. uncontrolled hypertension
  5. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:

    1. systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1
    2. OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1

10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:

a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.

9. Planned major changes in lifestyle [i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling] during the duration of the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Synbiotic

Synbiotic dietary supplement

Synbiotic

- Given daily for 56 days

Placebo-Komparator: Placebo

Identical looking placebo consisting of maltodextrin

Placebo

- Given daily for 56 days

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Bifidobacterium abundance
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing.

From baseline to end of intervention at 8 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stool frequency
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable.

From baseline to end of intervention at 8 weeks
Fecal acetate
Zeitfenster: From baseline to end of intervention at 8 weeks.

Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal propionate
Zeitfenster: From baseline to end of intervention at 8 weeks.

Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal butyrate
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Zonulin
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in serum zonulin from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Lipopolysaccharide binding protein (LPS-BP)
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in plasma LPS-BP from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Interleukin 6 (IL-6)
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in serum IL-6 from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
High-sensitivity C-Reactive Protein (hsCRP)
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in serum hsCRP from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Fecal Short-Chain Fatty Acids (SCFA)
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in composite measurement of fecal SCFAs panel with targeted metabolomics (GC-MSMS) from baseline to 8 weeks. Total composite is defined as: acetate + propionate + butyrate.

From baseline to end of intervention at 8 weeks
Stool consistency
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in mean stool consistency assessed daily from 2 weeks prior to baseline to daily 2 weeks prior to end-of intervention. Stool consistency will be assessed by Bristol stool chart scale rated Type 1 (separate hard lumps) to Type 7 (watery, no solid pieces). An increase in stool consistency is desirable.

From baseline to end of intervention at 8 weeks
Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score
Zeitfenster: From baseline to end of intervention at 8 weeks

Change in GSRS-IBS composite score from baseline to end-of-intervention visit. The GSRS-IBS questionnaire includes 13 items that measure the severity of IBS symptoms in five clusters (pain, bloating, constipation, diarrhea and early satiety) during the last seven days. A decrease is desirable.

From baseline to end of intervention at 8 weeks

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recovery of probiotic strains
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Recovery and colonization of strains by strain specific qPCR of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Total relative abundance of Bifidobacterium
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.

Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
Microbiome composition and taxonomic profiles
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Microbiome functional profiling
Zeitfenster: Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples

Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Plasma Metabolomics
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in blood metabolome as assessed by untargeted and targeted metabolomics from plasma samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Fecal metabolomics
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in fecal metabolome as assessed by untargeted and targeted metabolomics from fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Bacterial HMO utilization genes
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Abundance development over time of HMO degradation and modification genes such as Glycosyl hydrolases, encoded by probiotic supplements and endogenous gut species

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
HMO concentration in blood and feces
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in HMO in plasma and fecal samples after 3 and 8 weeks of supplementation

Baseline, 3 weeks and end of intervention at 8 weeks
Fecal pH
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in pH assessed using a pH meter in fecal samples

Baseline, 3 weeks and end of intervention at 8 weeks
Inflammatory Biomarkers
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in inflammatory biomarkers measured in serum

Baseline, 3 weeks and end of intervention at 8 weeks
Cardiometabolic Biomarkers
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in cardiometabolic biomarkers

Baseline, 3 weeks and end of intervention at 8 weeks
Cognitive function measured by the Trails Making Test (Parts A & B)
Zeitfenster: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using Trail Making Test (Parts A & B)

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Stroop Colour and Word Test
Zeitfenster: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Stroop Colour and Word Test

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Symbol Digit Modalities Test (SDMT)
Zeitfenster: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Symbol Digit Modalities Test (SDMT)

Baseline and end of intervention at 8 weeks
Health-related Quality of Life
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in health-related quality of life assessed by Short Form-36 (RAND SF-36)

Baseline, 3 weeks and end of intervention at 8 weeks
Gastrointestinal Symptoms Measured by the GSRS-IBS Total Score
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gastrointestinal symptoms by assessing the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). The outcome reflects the total composite score. A decrease is desirable.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
GSRS-IBS Pain Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.

Change in the gastrointestinal symptom pain assessed using GSRS-IBS subscale for Pain. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
GSRS-IBS Bloating Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom bloating assessed using GSRS-IBS subscale for bloating. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Constipation Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom constipation assessed using GSRS-IBS subscale for constipation. A decrease is desirable

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Diarrhea Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom Diarrhea assessed using GSRS-IBS subscale for Diarrhea. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Early Satiety Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom early satiety assessed using GSRS-IBS subscale for early satiety.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
Protein Composite Score
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks

Change in protein composite score measured using OLINK Reveal panel

Baseline, 3 weeks and end of intervention at 8 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Martin Buckley, Professor, Atlantia Clinical Trials Ltd

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. März 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

24. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. März 2026

Zuerst gepostet (Tatsächlich)

6. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • HHB-GI-2406
  • ECM4(i)11/12/2025 (Andere Kennung: Clinical Research Ethics Committee of the Cork Teaching Hospitals)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren